Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2022-06, Vol.197 (6), p.e82-e85 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e85 |
|---|---|
| container_issue | 6 |
| container_start_page | e82 |
| container_title | British journal of haematology |
| container_volume | 197 |
| creator | Baumelou, Marion Payssot, Alexandre Row, Celine Racine, Jessica Lafon, Ingrid Bastie, Jean‐Noél Chevreux, Steeve Chrétien, Marie‐Lorraine Maynadié, Marc Caillot, Denis Guy, Julien |
| description | |
| doi_str_mv | 10.1111/bjh.18103 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2638747568</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2675523356</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3533-63e4094f9ee5dca2f84c04732d6b4a1a15fa60171ba731eda54fd39e7f3c24243</originalsourceid><addsrcrecordid>eNp10cFO3DAQBmCrApVl20NfAFniAoeAHdtx9tiiLRQhcaHnaOJMul458WI7lLx9TRc4VKovlqxvflnzE_KFswuez2W73VzwmjPxgSy4qFRRcskPyIIxpgvOZH1EjmPcMsYFU_wjORKq1LpWqwV5XkNwMwWzsfiEA46J-p4OCHEK0DqkAaPtJnC0szG_Ih3xFyT7ZNNM7UjTBmkKCOl9dHLJ7vLgMKPzA1CIdBewsyb58AL8lIwf8BM57MFF_Px6L8nP7-uHq5vi7v76x9XXu8IIJURRCZRsJfsVouoMlH0tDZNalF3VSuDAVQ8V45q3oAXHDpTsO7FC3QtTylKKJTnb5-6Cf5wwpmaw0aBzMKKfYlNWotZSq6rO9PQfuvVTGPPvstJKlUKoKqvzvTLBxxiwb3bBDhDmhrPmpY4m19H8rSPbk9fEqR2we5dv-8_gcg9-W4fz_5Oab7c3-8g_k3CVLA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2675523356</pqid></control><display><type>article</type><title>Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Wiley Online Library Free Content</source><creator>Baumelou, Marion ; Payssot, Alexandre ; Row, Celine ; Racine, Jessica ; Lafon, Ingrid ; Bastie, Jean‐Noél ; Chevreux, Steeve ; Chrétien, Marie‐Lorraine ; Maynadié, Marc ; Caillot, Denis ; Guy, Julien</creator><creatorcontrib>Baumelou, Marion ; Payssot, Alexandre ; Row, Celine ; Racine, Jessica ; Lafon, Ingrid ; Bastie, Jean‐Noél ; Chevreux, Steeve ; Chrétien, Marie‐Lorraine ; Maynadié, Marc ; Caillot, Denis ; Guy, Julien</creatorcontrib><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18103</identifier><identifier>PMID: 35277859</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>early assessment ; Flow Cytometry ; Hematology ; Humans ; measurable residual disease ; Multiple myeloma ; Multiple Myeloma - drug therapy ; Neoplasm, Residual ; outcome ; Treatment Outcome</subject><ispartof>British journal of haematology, 2022-06, Vol.197 (6), p.e82-e85</ispartof><rights>2022 British Society for Haematology and John Wiley & Sons Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3533-63e4094f9ee5dca2f84c04732d6b4a1a15fa60171ba731eda54fd39e7f3c24243</citedby><cites>FETCH-LOGICAL-c3533-63e4094f9ee5dca2f84c04732d6b4a1a15fa60171ba731eda54fd39e7f3c24243</cites><orcidid>0000-0002-4666-9784</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.18103$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.18103$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27903,27904,45553,45554,46387,46811</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35277859$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baumelou, Marion</creatorcontrib><creatorcontrib>Payssot, Alexandre</creatorcontrib><creatorcontrib>Row, Celine</creatorcontrib><creatorcontrib>Racine, Jessica</creatorcontrib><creatorcontrib>Lafon, Ingrid</creatorcontrib><creatorcontrib>Bastie, Jean‐Noél</creatorcontrib><creatorcontrib>Chevreux, Steeve</creatorcontrib><creatorcontrib>Chrétien, Marie‐Lorraine</creatorcontrib><creatorcontrib>Maynadié, Marc</creatorcontrib><creatorcontrib>Caillot, Denis</creatorcontrib><creatorcontrib>Guy, Julien</creatorcontrib><title>Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><subject>early assessment</subject><subject>Flow Cytometry</subject><subject>Hematology</subject><subject>Humans</subject><subject>measurable residual disease</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - drug therapy</subject><subject>Neoplasm, Residual</subject><subject>outcome</subject><subject>Treatment Outcome</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10cFO3DAQBmCrApVl20NfAFniAoeAHdtx9tiiLRQhcaHnaOJMul458WI7lLx9TRc4VKovlqxvflnzE_KFswuez2W73VzwmjPxgSy4qFRRcskPyIIxpgvOZH1EjmPcMsYFU_wjORKq1LpWqwV5XkNwMwWzsfiEA46J-p4OCHEK0DqkAaPtJnC0szG_Ih3xFyT7ZNNM7UjTBmkKCOl9dHLJ7vLgMKPzA1CIdBewsyb58AL8lIwf8BM57MFF_Px6L8nP7-uHq5vi7v76x9XXu8IIJURRCZRsJfsVouoMlH0tDZNalF3VSuDAVQ8V45q3oAXHDpTsO7FC3QtTylKKJTnb5-6Cf5wwpmaw0aBzMKKfYlNWotZSq6rO9PQfuvVTGPPvstJKlUKoKqvzvTLBxxiwb3bBDhDmhrPmpY4m19H8rSPbk9fEqR2we5dv-8_gcg9-W4fz_5Oab7c3-8g_k3CVLA</recordid><startdate>202206</startdate><enddate>202206</enddate><creator>Baumelou, Marion</creator><creator>Payssot, Alexandre</creator><creator>Row, Celine</creator><creator>Racine, Jessica</creator><creator>Lafon, Ingrid</creator><creator>Bastie, Jean‐Noél</creator><creator>Chevreux, Steeve</creator><creator>Chrétien, Marie‐Lorraine</creator><creator>Maynadié, Marc</creator><creator>Caillot, Denis</creator><creator>Guy, Julien</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4666-9784</orcidid></search><sort><creationdate>202206</creationdate><title>Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome</title><author>Baumelou, Marion ; Payssot, Alexandre ; Row, Celine ; Racine, Jessica ; Lafon, Ingrid ; Bastie, Jean‐Noél ; Chevreux, Steeve ; Chrétien, Marie‐Lorraine ; Maynadié, Marc ; Caillot, Denis ; Guy, Julien</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3533-63e4094f9ee5dca2f84c04732d6b4a1a15fa60171ba731eda54fd39e7f3c24243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>early assessment</topic><topic>Flow Cytometry</topic><topic>Hematology</topic><topic>Humans</topic><topic>measurable residual disease</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - drug therapy</topic><topic>Neoplasm, Residual</topic><topic>outcome</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baumelou, Marion</creatorcontrib><creatorcontrib>Payssot, Alexandre</creatorcontrib><creatorcontrib>Row, Celine</creatorcontrib><creatorcontrib>Racine, Jessica</creatorcontrib><creatorcontrib>Lafon, Ingrid</creatorcontrib><creatorcontrib>Bastie, Jean‐Noél</creatorcontrib><creatorcontrib>Chevreux, Steeve</creatorcontrib><creatorcontrib>Chrétien, Marie‐Lorraine</creatorcontrib><creatorcontrib>Maynadié, Marc</creatorcontrib><creatorcontrib>Caillot, Denis</creatorcontrib><creatorcontrib>Guy, Julien</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baumelou, Marion</au><au>Payssot, Alexandre</au><au>Row, Celine</au><au>Racine, Jessica</au><au>Lafon, Ingrid</au><au>Bastie, Jean‐Noél</au><au>Chevreux, Steeve</au><au>Chrétien, Marie‐Lorraine</au><au>Maynadié, Marc</au><au>Caillot, Denis</au><au>Guy, Julien</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2022-06</date><risdate>2022</risdate><volume>197</volume><issue>6</issue><spage>e82</spage><epage>e85</epage><pages>e82-e85</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>35277859</pmid><doi>10.1111/bjh.18103</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-4666-9784</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2022-06, Vol.197 (6), p.e82-e85 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2638747568 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Wiley Online Library Free Content |
| subjects | early assessment Flow Cytometry Hematology Humans measurable residual disease Multiple myeloma Multiple Myeloma - drug therapy Neoplasm, Residual outcome Treatment Outcome |
| title | Early achievement of measurable residual disease negativity in the treatment of multiple myeloma as predictor of outcome |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T08%3A37%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20achievement%20of%20measurable%20residual%20disease%20negativity%20in%20the%20treatment%20of%20multiple%20myeloma%20as%20predictor%20of%20outcome&rft.jtitle=British%20journal%20of%20haematology&rft.au=Baumelou,%20Marion&rft.date=2022-06&rft.volume=197&rft.issue=6&rft.spage=e82&rft.epage=e85&rft.pages=e82-e85&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18103&rft_dat=%3Cproquest_cross%3E2675523356%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2675523356&rft_id=info:pmid/35277859&rfr_iscdi=true |